Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03359291
Other study ID # AC-055-122
Secondary ID
Status Completed
Phase Phase 1
First received November 13, 2017
Last updated December 18, 2017
Start date November 3, 2017
Est. completion date December 4, 2017

Study information

Verified date December 2017
Source Actelion
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this Phase 1 trial is to study a potential drug-drug interaction between macitentan and rosuvastatin, a model substrate of various transporter proteins (e.g. in the gut).


Description:

Rosuvastatin is a substrate of various transporter proteins including breast cancer resistance protein (BCRP) and organic anion-transporting polypeptides (OATP). It is unknown to which extent macitentan has an effect, if any, on BCRP transporters, especially intestinal BCRP. The primary purpose of this Phase 1 study is to investigate the effect of macitentan on the pharmacokinetics of rosuvastatin, a model BCRP substrate.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 4, 2017
Est. primary completion date December 4, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Principal Inclusion Criteria:

- Signed informed consent in the local language prior to any study-mandated procedure.

- Healthy male subjects aged between 18 and 55 years (inclusive) at screening.

- No clinically significant findings on the physical examination at screening.

- Body mass index of 18.0 to 30.0 kg/m2 (inclusive) at screening.

- Systolic blood pressure 100-140 mmHg, diastolic blood pressure 60-90 mmHg, and pulse rate 50-90 beats per minute (inclusive), measured on the dominant arm, after 5 min in the supine position at screening.

- 12-lead electrocardiogram (ECG) without clinically relevant abnormalities, measured after 5 min in the supine position at screening.

- Hematology and clinical chemistry test results not deviating from the normal range to a clinically relevant extent at screening.

- Negative results from urine drug screen and alcohol breath test at screening and Day -1.

- Ability to communicate well with the investigator, in the local language, and to understand and comply with the requirements of the study.

Principal Exclusion Criteria:

- Known allergic reactions or hypersensitivity to macitentan, rosuvastatin, any drug of the same classes, or any of their excipients.

- Any contraindication for rosuvastatin treatment.

- History or clinical evidence of myopathy.

- Subjects of Asian race.

- Known hypersensitivity or allergy to natural rubber latex.

- Values of hepatic aminotransferase (alanine aminotransferase and aspartate aminotransferase) outside of the normal range at screening.

- Hemoglobin or hematocrit outside of the normal range at screening.

- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment(s) (appendectomy and herniotomy allowed, cholecystectomy not allowed).

- Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions.

- Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture, veins with a tendency to rupture during or after puncture).

- Previous exposure to macitentan.

- Previous exposure to rosuvastatin.

- Treatment with another investigational drug within 3 months prior to screening or participation in more than 3 investigational drug studies within 1 year prior to screening.

- History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.

- Excessive caffeine consumption, defined as = 800 mg per day at screening.

- Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum or electronic cigarettes) within 3 months prior to screening and inability to refrain from nicotine intake from screening until End-Of-Study (EOS).

- Previous treatment with any prescribed medications (including vaccines) or over-the-counter (OTC) medications (including herbal medicines such as St John's Wort, homeopathic preparations, vitamins, and minerals) within 3 weeks prior to first study treatment administration.

- Loss of 250 mL or more of blood within 3 months prior to screening.

- Positive results from the hepatitis serology, except for vaccinated subjects or subjects with past but resolved hepatitis, at screening.

- Positive results from the HIV serology at screening.

- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.

- Legal incapacity or limited legal capacity at screening.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Rosuvastatin
Single oral dose of 10 mg rosuvastatin (film-coated tablet) on Day 1 and Day 10
Macitentan
Single oral dose of 30 mg macitentan (film-coated tablet) on Day 5 and 10 mg macitentan administered orally from Day 6 to Day 16

Locations

Country Name City State
Germany CRS Clinical Research Services Mannheim Mannheim

Sponsors (1)

Lead Sponsor Collaborator
Actelion

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUC(0-inf) of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B) AUC(0-inf) is the area under the plasma concentration-time curves of rosuvastatin, calculated from time zero to the extrapolated infinite time From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)
Primary Cmax of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B) Cmax is the maximum observed plasma concentration and is directly derived from the individual plasma concentration time curves of rosuvastatin From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)
Secondary tmax of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B) The time to reach maximum plasma concentration (tmax) of rosuvastatin From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)
Secondary t½ of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B) t½ is the terminal half-life of rosuvastatin and corresponds to the period of time required for the concentration levels of rosuvastatin to be reduced by one-half From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)
Secondary AUC(0-t) of rosuvastatin following administration of rosuvastatin alone (treatment A) and in combination with macitentan (treatment B) AUC(0-t) is the area under the plasma concentration-time curve from time zero to time t of the last measured concentration above the limit of quantification of rosuvastatin From Day1 to Day17 (treatment A: from Day1-Day5 and treatment B: from Day10-Day17)
Secondary Trough plasma concentrations of macitentan and its metabolite ACT-132577 Trough concentrations of macitentan and ACT-132577 are measured before oral administration of macitentan From Day5 to Day17
Secondary Change from baseline in supine blood pressure Change from baseline to each time point of measurement during study period From Day1 to end-of-study visit (Day 26-28)
Secondary Change from baseline in pulse rate Change from baseline to each time point of measurement during study period From Day1 to end-of-study visit (Day 26-28)
Secondary Change from baseline in heart rate (HR) Change from baseline to each time point of measurement during study period From Day1 to end-of-study visit (Day 26-28)
Secondary Change from baseline in ECG variables Change from baseline to each time point of measurement during study period in ECG variables: PR, QRS, QT, RR, and QT corrected for Bazett's and Fridericia's formulae (QTcB and QTcF, respectively) From Day1 to end-of-study visit (Day 26-28)
Secondary Change from baseline to end-of-study (EOS) in body weight Change in body weight measured in kg during study period From Day1 to end-of-study visit (Day 26-28)
Secondary Change from baseline in clinical laboratory tests Change from baseline to each time point of measurement during study period for clinical laboratory tests (hematology, clinical chemistry, serology) From Day1 to end-of-study visit (Day 26-28)
Secondary Incidence rate of treatment-emergent treatment-emergent adverse events (AEs) and serious adverse events (SAEs) Incidence rates of treatment-emergent AEs including abnormalities in ECG variables during each treatment as well as AEs leading to the discontinuation of study treatment. A treatment-emergent AE is any AE temporally associated with the use of a study treatment, whether or not considered related to the study treatment. From Day1 to follow-up period (Day46-48)
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1